

# Respiratory Viruses in Luxembourg (ReViLux)


Weekly report (28 – 06 March 2022)

## Executive Summary

The Sentinel Surveillance Network reported 2.71% of influenza-like illness, thus the baseline circulation threshold, according to the European Center for Disease Prevention and Control (ECDC). SARS-CoV-2 remains the most frequently detected virus over the last four weeks (40.0%), followed by influenza virus type A (34.7%) and human rhinovirus (12.0%).

Regarding SARS-CoV-2 genomic surveillance, the LNS sequenced 624 specimens from residents in Luxembourg in week 9 (of 4794 total cases in the Grand Duchy of Luxembourg; 13.0%). This exceeds the ECDC recommendations to detect emerging variants at 2.5%. Including PCR screening results, 1376 national specimens were analysed globally (28.7%).

The Omicron variant was the dominant one in the representative sample. The BA.2 lineage is now the most frequent one (67.0%), followed by BA.1 (32.8%). The analysis of target groups showed no statistically significant difference in the distribution of BA.1 and BA.2 according to collection setting and vaccination status. Additionally, two AY.4 specimens were also detected, and were found to carry mutations frequently associated with the Omicron variant.



## Introduction

The Laboratoire national de santé, as **National Reference Laboratory for Acute Respiratory Infections in Luxembourg**, performs close surveillance on respiratory viruses, with a special focus on SARS-CoV-2. There are currently two active projects:

- **The Sentinel Surveillance Network.** It provides a broad picture of respiratory diseases affecting the Luxembourgish population, based on its double monitoring system (syndromic and virological).
- **The National SARS-COV-2 Genomic Surveillance Program.** It enables detailed observation of SARS-CoV-2 mutations and variants through time and space, and also monitoring specific groups of interest.

The objective of the ReViLux is to inform public health actions in Luxembourg.

## Sentinel Surveillance Network

The **Sentinel Surveillance Network** aims at monitoring the circulating respiratory viruses, including SARS-CoV-2, and hence underpin public health actions. Following the World Health Organization (WHO) and European Centre for Disease Prevention and Control (ECDC) guidance, it focuses on cases of acute respiratory infection (ARI) and influenza-like illness (ILI).

The current influenza season started in week 40/2021, and the history of ILI consultations is displayed in Figure 1. A detailed summary of the number of ARI and ILI cases during the last four weeks is included in Table 1. In the week of study, 2.71% of consultations were reported as ILI, thus exceeding the threshold for baseline circulation, according to the ECDC (2.59%).

Table 1. Syndromic surveillance over the last 4 weeks.

Week	ARI		ILI		Total consultations
	N	%	N	%	
2022/6	65	16.80	9	2.33	387
2022/7	26	15.03	1	0.58	173
2022/8	49	20.68	6	2.53	237
2022/9	55	14.91	10	2.71	369

ARI: Acute Respiratory Infections; ILI: Influenza-Like Illness.




Figure 1. Percentage of patients with influenza-like illness over the last three seasons

Additionally, a selection of sentinel cases is further studied in order to monitor the circulation of respiratory viruses in the country, as shown in Figure 2. Over the last 4 weeks, influenza-virus-A was detected in 34.7% of positive specimens (including 2 co-infection cases), and influenza-virus-B in 4.0% (including 1 co-infection). These results are displayed more in detail in Table 2.




Figure 2. Distribution of respiratory viruses detected within the Sentinel Network, by week. Results from last two weeks are not yet consolidated.

Co-inf: co-infection; FLU-A: influenza virus A; FLU-B: influenza virus B; PIV: parainfluenza virus; RSV: respiratory syncytial virus; ADV: adenovirus; MPV: metapneumovirus; HRV: human rhinovirus; SC2: SARS-CoV-2.

Table 2. Distribution of respiratory viruses detected within the Sentinel Network over the last 4 weeks and during the current season.

Virus	Last 4 weeks		Current season	
	N*	%	N*	%
SARS-CoV-2	30	40.0	250	56.8
Human rhinovirus	9	12.0	100	22.7
Influenzavirus A	26	34.7	37	8.4
Metapneumovirus	4	5.3	16	3.6
Respiratory syncytial virus	2	2.7	15	3.4
Parainfluenzavirus	0	0.0	14	3.2
Adenovirus	1	1.3	5	1.1
Influenzavirus B	3	4.0	3	0.7
<b>Total</b>	<b>75</b>	<b>100.0</b>	<b>440</b>	<b>100.0</b>

\*Co-infection cases counted once for each virus detected.

## SARS-CoV-2 Genomic Surveillance

### The current sequencing strategy

The National Reference Laboratory for Acute Respiratory Infections at LNS receives SARS-CoV-2 positive samples (nasopharyngeal or oropharyngeal swabs analysed by RT-PCR) from the national network of laboratories and proceeds as follows:

- 1) Sequencing all specimens from hospital cases.
- 2) Sequencing all specimens from post-vaccination cases.
- 3) Sequencing specimens from clusters with high transmission.
- 4) Sequencing a representative sample of community cases.

The representative sample of community cases is a systematic selection from all SARS-CoV-2 positive cases registered in Luxembourg to detect emerging variants and early increases in their incidence and transmission within the community in Luxembourg. This sample is selected according to the ECDC guidelines.

Due to the emergence of the new Omicron variant of concern, as well as the high incidence rates in the European context, targeted PCR tests are carried systematically in order to detect potential Omicron cases within 24h from reception of the specimen. The PCR kits used target the following spike mutations: 69/70del, K417N, N501Y. The potential cases identified this way are then prioritised for confirmation by sequencing.

The LNS shares its sequencing results with GISAID EpiCov database periodically. SARS-CoV-2 lineages have been assigned based on Rambaut et al. using the Phylogenetic Assignment of Named Global Outbreak LINEages (pangolin) software (v3.1.20, pangoLEARN 2022-02-02). The Pango nomenclature is used in addition to the WHO nomenclature to enable easier visualization of links between any evolving variants and their ancestor (See nomenclature equivalences in Appendix 1).

### Screening and sequenced specimens




Figure 3. Flowchart of specimens collected during week 9/2022

In week 9, 4794 new cases were registered in Luxembourg; hence, the minimum sample size required to detect emerging variants at a 2.5% incidence is estimated to be 533 specimens (11.1%).

As shown in Figure 3, of all specimens received from the week of study, 1260 were screened by targeted PCR for the Omicron variant (including 1139 national specimens), in order to enable an earlier detection of potential Omicron cases (see results in the following section). In parallel, the microbial genomics unit at the LNS sequenced 705 specimens, including 624 national ones. The weekly sequencing coverage remains at 13.0% (624 out of 4794 cases registered in Luxembourg; see coverage trend in Figure 4), which exceeds the recommended sample size. Overall, 1376 national specimens were analysed either by sequencing or screening (28.7%).




Figure 4. National coverage based on weekly number of positive cases in Luxembourg. The coverage from the latest weeks might not be consolidated yet.

## Omicron screening results

As shown in Figure 5, of the 1260 specimens from week 8 which were screened by targeted PCR, all were identified as potential Omicron cases: 66.0% BA.2 and 34.0% BA.1.




Figure 5. Number of specimens included in the screening for the Omicron variant by date of collection. Results more recent than the week of study are not yet consolidated.

## Circulating lineage detection

The distribution of successfully assigned lineages within the national selection is shown in Figure 6. Regarding Delta AY sublineages, only a selection is displayed, based on their prevalence during the last 10 weeks (min. 1%). This distribution is further detailed for the last 2 weeks in Table 4.

The Omicron variant remains the dominant one within the representative sample. The most frequent lineage is now BA.2 (67.0%), followed by BA.1 (32.8%).

A summary of the VOCs assigned among all specimens sequenced (including non-residents) during the last two weeks and since the beginning of the sequencing activity is shown in Table 5.

Table 4. Distribution of SARS-CoV-2 lineages detected within the representative sample during the last two weeks (previously reported cases might be updated by retrospective analysis).

Variant	Previous week			Current week		
	N	%	CI %	N	%	CI %
Omicron	532	100.0	-	532	99.8	99.4 – 100.0
BA.1	277	52.1	47.8 – 56.3	175	32.8	28.8 – 36.8
BA.2	255	47.9	43.7 – 52.2	357	67.0	63.0 – 71.0
BA.1.1	0	-	-	0	-	-
Delta	0	-	-	1	0.2	0.0 – 0.6
Beta	0	-	-	0	-	-
Gamma	0	-	-	0	-	-
Others	0	-	-	0	-	-
<b>Total</b>	<b>532</b>	<b>100.0</b>	<b>-</b>	<b>533</b>	<b>100.0</b>	<b>-</b>




Figure 6. Distribution of lineages within the representative sample during the last 10 weeks.

Table 5. Distribution of VOCs within all samples sequenced (including non-residents)

Variant	Previous week		Current week		Cumulative count
	N	%	N	%	N
Delta	5	0.6	2	0.3	12 501
Omicron	772	99.4	652	69.7	8636
BA.1	407	49.5	201	30.7	7170
BA.2	411	49.9	451	69.0	1462
BA.1.1	0	-	0	-	4
Gamma	0	-	0	-	1305
Beta	0	-	0	-	1255
Other	0	-	0	-	12 167
<b>Total</b>	<b>823</b>	<b>100.0</b>	<b>654</b>	<b>100.0</b>	<b>34 123</b>

## Target groups

The LNS prioritises the sequencing of specimens collected at hospitals. These may belong to either outpatients or inpatients, and patients hospitalised for reasons other than COVID-19 might also be included. Therefore, not all hospital specimens can be attributed to severe COVID-19 cases. The distribution of Omicron lineages (BA.1 and BA.2) was studied by origin of the specimen (hospital or community) (Table 6), but no statistically significant difference was found ( $p > 0.1$ ). Only specimens from the latest 3 weeks were included in order to avoid bias by differing epidemiological contexts.

Table 6. Comparison of Omicron lineages distribution by sampling setting.

	Community	Hospital
Omicron BA.1	52.8%	51.3%
Omicron BA.2	47.2%	48.7%
Total	100.0%	100.0%

Number of cases: General = 1914, Hospital = 474.  $P$  value  $> 0.1$  ( $\chi^2$ ).

Similarly, the distribution of VOC cases was studied by vaccination status (fully vaccinated with 2 or more doses vs non-vaccinated) (Table 7), but no statistically significant difference was found either ( $p > 0.1$ ). This suggests that BA.1 and BA.2 may have a similar vaccine escape rate, which should be further studied.

Table 7. Comparison of VOC distribution by vaccination status.

	Not vaccinated	Fully vaccinated
Omicron BA.1	56.6%	60.1%
Omicron BA.2	43.4%	39.9%
Total	100.0%	100.0%

Number of cases: Not vaccinated = 452, Fully vaccinated = 897.  $P$  value  $> 0.1$  ( $\chi^2$ ).

## Mutation surveillance

In addition to the surveillance of SARS-CoV-2 variants, the LNS monitors the occurrence of SARS-CoV-2 mutations reported to have a clinical and epidemiological relevance. This complementary surveillance enables us to detect unexpected mutations among the specimens sequenced. Newly acquired mutations may occur and their early detection might be key to expect changes in the epidemic evolution. Following ECDC guidance, the LNS is currently monitoring 42 mutations to the spike protein frequently associated to VOCs. As each VOC is characterised by a set of defining mutations, which are expected to be highly present, it is interesting to analyse the non-defining ones. Among the specimens collected over the last four weeks, the following mutations were detected (minimum 1% prevalence):

- BA.1 specimens:
  - o A701V (in at least 4.3%), frequently associated to the Beta variant.
- BA.2 specimens:
  - o A67V, del69-70, T95I, L981F (each in at least 1.15%), frequently associated to Omicron BA.1.
- AY.4 specimens: two specimens were found to carry several mutations frequently associated to Omicron: T95I, T547K, N679K, P681H, N764K, D796Y, N856K, Q954H, N969K, L981F.

Concerning BA.1 specimens, the A701V mutation continues to show a decreasing trend and remains below the rate in the European region. Concerning BA.2 specimens, all aforementioned mutations also showed decreasing trends, but still higher than in the European region (<1%, according to GISAID), so they will remain under monitoring. Finally, regarding the AY.4 sharing Omicron mutations, similar specimens were also detected in other countries in Europe, mainly France and Denmark (according to GISAID), and it will remain under surveillance.

## References

Centers for Disease Control and Prevention. SARS-CoV-2 Variant Classifications and Definitions. Retrieved 14 March 2022, from <https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-info.html>

COVID-19 Data Portal - accelerating scientific research through data. (2021). Retrieved 14 March 2022, from <https://www.covid19dataportal.org/sequences>

Direção-Geral da Saúde. Relatório de Situação. Retrieved 14 March 2022, from <https://covid19.min-saude.pt/relatorio-de-situacao/>

European Centre for Disease Prevention and Control. Guidance for representative and targeted genomic SARS-CoV-2 monitoring – 3 May 2021. ECDC : Stockholm ; 2021

European Centre for Disease Prevention and Control. SARS-CoV-2 variants of concern. Retrieved 14 March 2022, from <https://www.ecdc.europa.eu/en/covid-19/variants-concern>

Genomic sequencing of SARS-CoV-2: a guide to implementation for maximum impact on public health. Geneva: World Health Organization; 2021.

GISAID. EpiCoV – Pandemic coronavirus causing COVID-19. Retrieved 14 mars 2022, from <https://www.gisaid.org>

GitHub - cov-lineages/pangolin: Software package for assigning SARS-CoV-2 genome sequences to global lineages. (2021). Retrieved 14 March 2022, from <https://github.com/cov-lineages/pangolin>

Hadfield J., Megill C., Bell S., Huddleston J., Potter B., Callender C. et al. (2018). Nextstrain: real-time tracking of pathogen evolution. *Bioinformatics*, 34(23), 4121-4123. doi: 10.1093/bioinformatics/bty407

Instituto Nacional de Saúde Doutor Ricardo Jorge. Diversidade genética do novo coronavírus SARS-CoV-2 (COVID-19) em Portugal. Retrieved 14 March 2022, from <https://insaflu.insa.pt/covid19/>

Pango Network. New AY lineages. Retrieved 14 March 2022, from: <https://www.pango.network/new-ay-lineages-and-an-update-to-ay-4-ay-12/>

Rambaut A., Holmes E., O’Toole Á., Hill V., McCrone J., Ruis C. et al. (2020). A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology. *Nature Microbiology*, 5(11), 1403-1407. doi: 10.1038/s41564-020-0770-5

Robert Koch Institut. Aktueller Lage-/Situationsbericht des RKI zu COVID-19. Retrieved 14 March 2022, from [https://www.rki.de/DE/Content/InfAZ/N/Neuartiges\\_Coronavirus/Situationsberichte/Gesamt.html;jsessionid=69BC18053F9591C56EB148E463103DB7.internet101](https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/Situationsberichte/Gesamt.html;jsessionid=69BC18053F9591C56EB148E463103DB7.internet101)

Santé publique France. Coronavirus : chiffres clés et évolution de la COVID-19 en France et dans le Monde. Retrieved 14 March 2022, from <https://www.santepubliquefrance.fr/dossiers/coronavirus-covid-19/coronavirus-chiffres-cles-et-evolution-de-la-covid-19-en-france-et-dans-le-monde>

Santé publique France. Enquêtes Flash : évaluation de la circulation des variants du SARS-CoV-2 en France. Retrieved 14 March 2022, from <https://www.santepubliquefrance.fr/etudes-et-enquetes/enquetes-flash-evaluation-de-la-circulation-des-variants-du-sars-cov-2-en-france>

Sciensano. COVID-19 – Bulletin épidémiologique hebdomadaire. Retrieved 14 March 2022, from <https://covid-19.sciensano.be/fr/covid-19-situation-epidemiologique>

The Luxembourgish data platform. COVID-19: Rapports hebdomadaires. Retrieved 14 March 2022, from <https://data.public.lu/en/datasets/covid-19-rapports-hebdomadaires/>

## Appendices

### Appendix 1: SARS-CoV-2 variants of concern

#### According to the ECDC

Table A1-a. Nomenclature for variants of concern by the European Centre for Disease Prevention and Control (ECDC)

WHO label	Pango lineage*	Spike mutations of interest	First detection	transmission	Evidence for impact on:	
					immunity	severity
<b>Beta</b>	B.1.351	K417N, E484K, N501Y, D614G, A701V	South Africa, Sept 2020	Increased (v)	Increased (v)	Increased (v)
<b>Gamma</b>	P.1	K417T, E484K, N501Y, D614G, H655Y	Brazil, Dec 2020	Increased (v)	Increased (v)	Increased (v)
<b>Delta</b>	B.1.617.2	L452R, T478K, D614G, P681R	India, Dec 2020	Increased (v)	Increased (v)	Increased (v)
<b>Omicron</b>	B.1.1.529	**	South Africa, Botswana, Nov 2021	Increased (v)	Increased (v)	Reduced (v)

WHO: World Health Organization. (v): evidence derived from the variant itself; (m): evidence derived from mutations associated with the variant.

\*All sub-lineages included.

\*\*A67V, Δ69-70, T95I, G142D, Δ143-145, N211I, Δ212, ins215EPE, G339D, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H, T547K, D614G, H655Y, N679K, P681H, N764K, D796Y, N856K, Q954H, N969K, L981F.

Adapted from ECDC – SARS-CoV-2 variants of concern (<https://www.ecdc.europa.eu/en/covid-19/variants-concern>).

## According to the WHO

Table A1-b. Nomenclature for variants of concern by the World Health Organization (WHO)

WHO label	Pango lineage*	GISAID clade/lineage	Nextstrain clade	Additional amino acid changes monitored	Earliest documented samples	Date of designation
<b>Alpha</b>	B.1.1.7 <sup>#</sup>	GRY (formerly GR/501Y.V1)	20I (V1)	+S:484K +S:452R	United Kingdom, Sep-2020	18-Dec-2020
<b>Beta</b>	B.1.351	GH/501Y.V2	20H (V2)	+S:L18F	South Africa, May-2020	18-Dec-2020
<b>Gamma</b>	P.1	GR/501Y.V3	20J (V3)	+S:681H	Brazil, Nov-2020	11-Jan-2021
<b>Delta</b>	B.1.617.2 <sup>§</sup>	GK	21A, 21I, 21J	+S:417N +S:484K	India, Oct-2020	VOI: 4-Apr-2021 VOC: 11-May-2021
<b>Omicron</b>	B.1.1.529 <sup>°</sup>	GRA	21K, 21L, 21M	+S:R346K	Multiple countries, Nov-2021	VUM: 24-Nov-2021 VOC: 26-Nov-2021

\*All sublineages included. # includes all Q sublineages. § includes all AY sublineages. ° includes all BA sublineages

Adapted from WHO - Tracking SARS-CoV-2 variants (<https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/>)